Previous studies reported that elevated serum uric acid level was associated with
greater coronary lipid plaque. Xanthine oxidoreductase (XOR) is a rate-limiting enzyme
in purine metabolism and is believed to play important roles in coronary atherosclerosis.
However, the relation between XOR and coronary lipid plaque is unclear. Patients with
stable coronary artery disease who underwent elective percutaneous coronary intervention
under near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) guidance were
prospectively included. They were divided into 3 groups according to plasma XOR activities
based on a previous report: low, normal, and high. Quantitative coronary angiography
and gray-scale IVUS were analyzed. The primary end point was coronary lipid plaques
in a nontarget vessel assessed by NIRS-IVUS with lipid core burden index (LCBI) and
maximum LCBI in 4 mm (maxLCBI4mm). Out of 68 patients, 26, 31, and 11 patients were classified as low, normal, and
high XOR activity groups. Quantitative coronary angiography demonstrated that the
high XOR activity group had longer lesion length, smaller minimum lumen diameter,
and higher percentage of diameter stenosis in a nontarget vessel among the 3 groups.
Gray-scale IVUS analysis also showed smaller lumen area in the high XOR activity group
than the others. LCBI (102.1 ± 56.5 vs 65.6 ± 48.5 vs 55.6 ± 37.8, p = 0.04) and maxLCBI4mm (474.4 ± 171.6 vs 347.4 ± 181.6, 294.0 ± 155.9, p = 0.04) in a nontarget vessel were
significantly higher in the high XOR group than in the normal and low groups. In conclusion,
elevated XOR activity was associated with coronary lipid-rich plaque in a nontarget
vessel in patients with stable coronary artery disease.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Relation of serum uric acid to cardiovascular disease.Int J Cardiol. 2016; 213: 4-7
- Relation of lipid content of coronary plaque to level of serum uric acid.Am J Cardiol. 2015; 116: 1346-1350
- Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease.J Atheroscler Thromb. 2016; 23: 932-939
- Identification of uric acid and xanthine oxidase in atherosclerotic plaque.Am J Cardiol. 2001; 88: 188-191
- A highly sensitive assay for xanthine oxidoreductase activity using a combination of [(13) C2,(15) N2]xanthine and liquid chromatography/triple quadrupole mass spectrometry.J Labelled Comp Radiopharm. 2016; 59: 214-220
- A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS.J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1039: 51-58
- Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure.Int J Cardiol. 2017; 228: 151-157
- Large lipid-rich coronary plaques detected by near-infrared spectroscopy at non-stented sites in the target artery identify patients likely to experience future major adverse cardiovascular events.Eur Heart J Cardiovasc Imaging. 2016; 17: 393-399
- Clinical expert consensus document on standards for measurements and assessment of intravascular ultrasound from the Japanese Association of Cardiovascular Intervention and Therapeutics.Cardiovasc Interv Ther. 2019; https://doi.org/10.1007/s12928-019-00625-6
- Current clinical use of intravascular ultrasound imaging to guide percutaneous coronary interventions.Cardiovasc Interv Ther. 2019; https://doi.org/10.1007/s12928-019-00603-y
- Plaque characterization to inform the prediction and prevention of periprocedural myocardial infarction during percutaneous coronary intervention: the CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow).JACC Cardiovasc Interv. 2015; 8: 927-936
- Lipid-core burden response to stent implantation assessed with near-infrared spectroscopy and intravascular ultrasound evaluation in patients with myocardial infarction.Cardiovasc Revasc Med. 2017; 18: 182-189
- Plasma xanthine oxidoreductase activity as a novel biomarker of metabolic disorders in a general population.Circ J. 2018; 82: 1892-1899
- Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.Atherosclerosis. 2014; 237: 562-567
- Combined IVUS and NIRS detection of fibroatheromas: histopathological validation in human coronary arteries.JACC Cardiovasc Imaging. 2015; 8: 184-194
- Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease.J Am Coll Cardiol. 2014; 64: 2510-2518
- Long-term follow-up after near-infrared spectroscopy coronary imaging: insights from the lipid core plaque association with clinical events (ORACLE-NIRS) registry.Cardiovasc Revasc Med. 2017; 18: 177-181
- Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up.Eur Heart J. 2018; 39: 295-302
- Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study.Lancet. 2019; 394: 1629-1637
- Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.Cardiovasc Ther. 2012; 30: 217-226
- Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial.Heart. 2014; 100: 1085-1092
- Febuxostat for cerebral and cardiorenovascular events prevention study.Eur Heart J. 2019; 40: 1778-1786
- Current clinical applications of coronary optical coherence tomography.Cardiovasc Interv Ther. 2018; 33: 1-10
- Expert consensus statement for quantitative measurement and morphological assessment of optical coherence tomography.Cardiovasc Interv Ther. 2019; https://doi.org/10.1007/s12928-019-00626-5
Article info
Publication history
Published online: January 09, 2020
Received in revised form:
December 19,
2019
Received:
November 1,
2019
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
